The biggest stories of the day delivered to your inbox.

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Tourmaline Bio Inc (NASDAQ:TRML) increased during the last reporting period, rising from 2.71M to 3.13M. This put 13.67% of the company's publicly available shares short.

The biggest stories of the day delivered to your inbox.